BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing. Clin Pharmacokinet. 2002;41:453-470. [PMID: 12083975 DOI: 10.2165/00003088-200241070-00001] [Cited by in Crossref: 111] [Cited by in F6Publishing: 97] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts ACG. The impact of Cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidem Drug Safe 2006;15:107-14. [DOI: 10.1002/pds.1173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
2 Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-90. [PMID: 16968950 DOI: 10.1124/pr.58.3.6] [Cited by in Crossref: 258] [Cited by in F6Publishing: 191] [Article Influence: 17.2] [Reference Citation Analysis]
3 Zhou S. Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II. Clinical Pharmacokinetics 2009;48:761-804. [DOI: 10.2165/11318070-000000000-00000] [Cited by in Crossref: 228] [Cited by in F6Publishing: 200] [Article Influence: 19.0] [Reference Citation Analysis]
4 Nordin C, Dahl M, Eklundh T, Eriksson M, Sjöberg S. CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype. European Neuropsychopharmacology 2003;13:333-5. [DOI: 10.1016/s0924-977x(03)00033-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
5 Luo X, Zhu L, Wu W, Sheng X, Cai N, Liu S, Cheng Z. Simultaneous Determination of 6β-Hydroxycortisol and 6β-Hydroxycortisone in Human Urine by LC with UV Absorbance Detection. Chroma 2009;70:1215-9. [DOI: 10.1365/s10337-009-1267-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic Variability of Aripiprazole and the Active Metabolite Dehydroaripiprazole in Psychiatric Patients. Therapeutic Drug Monitoring 2006;28:744-9. [DOI: 10.1097/01.ftd.0000249944.42859.bf] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
7 Crescenti A, Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A. CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. Clin Exp Pharmacol Physiol 2008;35:807-11. [DOI: 10.1111/j.1440-1681.2008.04918.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
8 Williams MS. Can Genomics Deliver on the Promise of Improved Outcomes and Reduced Costs?: Background and Recommendations for Health Insurers. Disease Management & Health Outcomes 2003;11:277-90. [DOI: 10.2165/00115677-200311050-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Bondy B. Pharmacogenomics in depression and antidepressants. Dialogues Clin Neurosci 2005;7:223-30. [PMID: 16156381 [PMID: 16156381 DOI: 10.31887/dcns.2005.7.3/bbondy] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
10 Cai X, Wang RW, Edom RW, Evans DC, Shou M, Rodrigues AD, Liu W, Dean DC, Baillie TA. VALIDATION OF (-)- N -3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES. Drug Metab Dispos 2004;32:584-6. [DOI: 10.1124/dmd.32.6.584] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
11 Mann MW, Pons G. Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy: A Review. CNS Drugs 2007;21:143-64. [DOI: 10.2165/00023210-200721020-00005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
12 Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl) 2004;175:1-6. [PMID: 15221198 DOI: 10.1007/s00213-004-1922-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
13 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Boston: Springer US; 2005. pp. 377-530. [DOI: 10.1007/0-387-27447-2_10] [Cited by in Crossref: 176] [Cited by in F6Publishing: 95] [Reference Citation Analysis]
14 de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-73. [PMID: 15883149 DOI: 10.1176/appi.psy.46.3.262] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 5.1] [Reference Citation Analysis]
15 Casley WL, Leblanc-westwood CA. Assay for the simultaneous detection of the *1C and *1F alleles of the CYP1A2 gene by real-time polymerase chain reaction and melting curve analysis. Psychiatric Genetics 2006;16:81-3. [DOI: 10.1097/01.ypg.0000185030.35558.6d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
16 Rodríguez-antona C, Gurwitz D, de Leon J, Llerena A, Kirchheiner J, de Mesa EG, Ibarreta D. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost–effectiveness studies. Pharmacogenomics 2009;10:685-99. [DOI: 10.2217/pgs.09.15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
17 Kim E, Yu K, Cho J, Shin Y, Yoo SY, Kim YY, Jang I, Shin S, Kwon JS. Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol Clin Exp 2006;21:519-28. [DOI: 10.1002/hup.806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
18 Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med 2011;4:123-36. [PMID: 23226058 DOI: 10.2147/PGPM.S15497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
19 Jaquenoud Sirot E, Willem van der Velden J, Rentsch K, Eap CB, Baumann P. Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance: . Drug Safety 2006;29:735-68. [DOI: 10.2165/00002018-200629090-00001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
20 Zhornitsky S, Stip E. Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment 2012;2012:407171. [PMID: 22966436 DOI: 10.1155/2012/407171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
21 Uhr M, Namendorf C, Grauer MT, Rosenhagen M, Ebinger M. P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharmacol 2004;18:509-15. [PMID: 15582917 DOI: 10.1177/0269881104047278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
22 Zhornitsky S, Rizkallah É, Pampoulova T, Chiasson J, Stip E, Rompré P, Potvin S. Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis. Journal of Clinical Psychopharmacology 2010;30:417-24. [DOI: 10.1097/jcp.0b013e3181e7810a] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
23 Subuh Surja AA, Reynolds KK, Linder MW, El-Mallakh RS. Pharmacogenetic testing of CYP2D6 in patients with aripiprazole-related extrapyramidal symptoms: a case-control study. Per Med 2008;5:361-5. [PMID: 29783455 DOI: 10.2217/17410541.5.4.361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
24 Lane H, Lee C, Liu Y, Chang W. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 2005;6:139-49. [DOI: 10.1517/14622416.6.2.139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
25 Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y. EVIDENCE FOR THE VALIDITY OF CORTISOL 6β-HYDROXYLATION CLEARANCE AS A NEW INDEX FOR IN VIVO CYTOCHROME P450 3A PHENOTYPING IN HUMANS. Drug Metab Dispos 2003;31:1283-7. [DOI: 10.1124/dmd.31.11.1283] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
26 Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32. [PMID: 19411165 DOI: 10.1016/j.euroneuro.2009.04.003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
27 Zarcone J, Napolitano D, Valdovinos M. Measurement of problem behaviour during medication evaluations. J Intellect Disabil Res 2008;52:1015-28. [PMID: 18717764 DOI: 10.1111/j.1365-2788.2008.01109.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
28 Ozdemir V, Gunes A, Dahl M, Scordo MG, Williams-jones B, Someya T. Could endogenous substrates of drug-metabolizing enzymes influence constitutive physiology and drug target responsiveness? Pharmacogenomics 2006;7:1199-210. [DOI: 10.2217/14622416.7.8.1199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
29 Foster A, Wang Z, Usman M, Stirewalt E, Buckley P. Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. Neuropsychiatr Dis Treat 2007;3:965-73. [PMID: 19300635 DOI: 10.2147/ndt.s1752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Skrętkowicz J, Barańska M, Kaczorowska A, Rychlik-Sych M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic lupus erythematosus. Arch Med Sci 2011;7:864-9. [PMID: 22291833 DOI: 10.5114/aoms.2011.25563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
31 Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526. [PMID: 18001838 DOI: 10.1016/j.pharmthera.2007.09.004] [Cited by in Crossref: 736] [Cited by in F6Publishing: 647] [Article Influence: 52.6] [Reference Citation Analysis]
32 Luo X, Li XM, Hu ZY, Cheng ZN. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 2009;30:1323-9. [PMID: 19701237 DOI: 10.1038/aps.2009.116] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
33 Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in the therapy of schizophrenia. Pharm World Sci 2005;27:20-30. [DOI: 10.1007/s11096-004-1731-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
34 Trzcinski R, Skretkowicz J, Dziki A, Rychlik-Sych M, Baranska M. Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease. Dig Dis Sci. 2010;55:1037-1043. [PMID: 19437119 DOI: 10.1007/s10620-009-0816-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Dorado P, Peñas-Lledó EM, Llerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007;8:1597-608. [PMID: 18034624 DOI: 10.2217/14622416.8.11.1597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
36 Brandon EFA, Sparidans RW, Guijt K, Löwenthal S, Meijerman I, Beijnen JH, Schellens JHM. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug. Invest New Drugs 2006;24:3-14. [DOI: 10.1007/s10637-005-4538-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
37 Llerena A, Dorado P, Peñas-lledó EM, Cáceres MC, De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 2007;7:408-10. [DOI: 10.1038/sj.tpj.6500439] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
38 Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003;59:45-50. [PMID: 12682803 DOI: 10.1007/s00228-003-0576-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
39 Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004;174:477-89. [PMID: 15243737 DOI: 10.1007/s00213-004-1949-9] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 3.8] [Reference Citation Analysis]
40 Panagiotidis G, Arthur HW, Lindh JD, Dahl M, Sjöqvist F. Depot Haloperidol Treatment in Outpatients With Schizophrenia on Monotherapy: Impact of CYP2D6 Polymorphism on Pharmacokinetics and Treatment Outcome. Therapeutic Drug Monitoring 2007;29:417-22. [DOI: 10.1097/ftd.0b013e31811f394d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
41 Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 2005;360:1563-70. [PMID: 16096104 DOI: 10.1098/rstb.2005.1685] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
42 Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet. 2009;48:63-70. [PMID: 19071885 DOI: 10.2165/0003088-200948010-00005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
43 Tay JK, Tan CH, Chong SA, Tan EC. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1297-302. [PMID: 17611010 DOI: 10.1016/j.pnpbp.2007.05.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
44 Landino J, Buckley J, Roy JM, Villagra D, Gorowski K, Kocherla M, Windemuth A, Ruaño G. Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing: CYP450 DNA typing guides psychopharmacotherapy. Journal of the American Academy of Nurse Practitioners 2011;23:459-63. [DOI: 10.1111/j.1745-7599.2011.00640.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
45 Mannheimer B, Holm J, Koukel L, Bertilsson L, Osby U, Eliasson E. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. Eur J Clin Pharmacol 2014;70:695-9. [PMID: 24643635 DOI: 10.1007/s00228-014-1664-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
46 Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003;33 Suppl 2:17-22. [PMID: 14641552 DOI: 10.1046/j.1365-2362.33.s2.3.x] [Cited by in Crossref: 148] [Cited by in F6Publishing: 125] [Article Influence: 8.7] [Reference Citation Analysis]
47 Ruoho AE. How the monoamine transporter garden grows. Mol Pharmacol 2005;68:272-4. [PMID: 15911691 DOI: 10.1124/mol.105.014951] [Reference Citation Analysis]
48 Lozupone M, Panza F, Stella E, La Montagna M, Bisceglia P, Miscio G, Galizia I, Daniele A, di Mauro L, Bellomo A, Logroscino G, Greco A, Seripa D. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? Expert Opinion on Drug Metabolism & Toxicology 2016;13:259-77. [DOI: 10.1080/17425255.2017.1246533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
49 Panza F, Lozupone M, Stella E, Miscio G, La Montagna M, Daniele A, di Mauro L, Bellomo A, Logroscino G, Greco A, Seripa D. The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes. Expert Review of Precision Medicine and Drug Development 2016;1:431-42. [DOI: 10.1080/23808993.2016.1232148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004;27:145-72. [PMID: 14756578 DOI: 10.2165/00002018-200427030-00001] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
51 Kirchheiner J, Nickchen K, Bauer M, Wong M, Licinio J, Roots I, Brockmöller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-73. [DOI: 10.1038/sj.mp.4001494] [Cited by in Crossref: 494] [Cited by in F6Publishing: 412] [Article Influence: 29.1] [Reference Citation Analysis]
52 Cascorbi I, Bruhn O, Werk AN. Challenges in pharmacogenetics. Eur J Clin Pharmacol 2013;69:17-23. [DOI: 10.1007/s00228-013-1492-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
53 Sjöqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007;81:899-902. [PMID: 17392719 DOI: 10.1038/sj.clpt.6100188] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
54 Hu Z, Zhao Y, Wu D, Cheng Z. Endogenous cortisol 6β-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clinica Chimica Acta 2009;408:92-7. [DOI: 10.1016/j.cca.2009.07.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
55 Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C, Gaedigk A, Leeder JS, McEvoy JP, Weale ME, Goldstein DB. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008;10:720-9. [PMID: 18813134 DOI: 10.1097/GIM.0b013e3181863239] [Cited by in Crossref: 33] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
56 Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, Widén J, Svensson J, Albers LJ, Kennedy JL, Endrenyi L, Kalow W. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited. Pharmacogenetics and Genomics 2007;17:339-47. [DOI: 10.1097/fpc.0b013e32801a3c10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
57 Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005;360:1617-38. [PMID: 16096112 DOI: 10.1098/rstb.2005.1693] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
58 Jia Y, Yu X, Zhang B, Yuan Y, Xu Q, Shen Y, Shen Y. No association between polymorphisms in three genes of cytochrome p450 family and paranoid schizophrenia in northern Chinese Han population. Eur Psychiatry 2004;19:374-6. [PMID: 15363478 DOI: 10.1016/j.eurpsy.2004.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
59 Preskorn SH. The Difference Between the Formal and the Functional Dose: The Case of the Patient on Thioridazine and Fluvoxamine: . Journal of Psychiatric Practice 2005;11:192-6. [DOI: 10.1097/00131746-200505000-00006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
60 Baumann P, Ulrich S, Eckermann G, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G, Hiemke C; Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsyhiatrie - Therapeutic Drug Monitoring group. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci 2005;7:231-47. [PMID: 16156382 [PMID: 16156382 DOI: 10.31887/dcns.2005.7.3/pbaumann] [Cited by in Crossref: 14] [Article Influence: 0.9] [Reference Citation Analysis]
61 Llerena A, Berecz R, Dorado P, González AP, Peñas-lledó EM, De la Rubia A. CYP2C9 gene and susceptibility to major depressive disorder. Pharmacogenomics J 2003;3:300-2. [DOI: 10.1038/sj.tpj.6500197] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
62 Cattaneo D, Perico N, Remuzzi G. From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy: From Pharmacokinetics to Pharmacogenomics. American Journal of Transplantation 2004;4:299-310. [DOI: 10.1111/j.1600-6143.2004.00312.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
63 Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25:193-200. [PMID: 15063083 DOI: 10.1016/j.tips.2004.02.007] [Cited by in Crossref: 396] [Cited by in F6Publishing: 328] [Article Influence: 23.3] [Reference Citation Analysis]
64 Panza F, Lozupone M, Stella E, Lofano L, Gravina C, Urbano M, Daniele A, Bellomo A, Logroscino G, Greco A, Seripa D. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics 2016;16:1357-69. [DOI: 10.1080/14737175.2016.1204913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
65 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
66 Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases 2003;42:906-25. [DOI: 10.1016/j.ajkd.2003.07.019] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
67 Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 2003; 9(2): 359-363 [PMID: 12532467 DOI: 10.3748/wjg.v9.i2.359] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
68 Shibasaki H, Hosoda K, Goto M, Suzuki A, Yokokawa A, Ishii K, Furuta T. Intraindividual and Interindividual Variabilities in Endogenous Cortisol 6 β -Hydroxylation Clearance as an Index for In Vivo CYP3A Phenotyping in Humans. Drug Metab Dispos 2013;41:475-9. [DOI: 10.1124/dmd.112.048561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
69 Salloum NC, McCarthy MJ, Leckband SG, Kelsoe JR. Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Med 2014;12:90. [PMID: 24885933 DOI: 10.1186/1741-7015-12-90] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
70 Guengerich FP. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 523-785. [DOI: 10.1007/978-3-319-12108-6_9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
71 Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics. 2006;7:889-908. [PMID: 16981848 DOI: 10.2217/14622416.7.6.889] [Cited by in Crossref: 137] [Cited by in F6Publishing: 110] [Article Influence: 9.1] [Reference Citation Analysis]
72 Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13. [PMID: 15492763 DOI: 10.1038/sj.tpj.6500285] [Cited by in Crossref: 699] [Cited by in F6Publishing: 599] [Article Influence: 43.7] [Reference Citation Analysis]
73 Matsumoto C, Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004;14:209-13. [PMID: 15564895 DOI: 10.1097/00041444-200412000-00008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
74 Filimonova AA, Ziganshina LE, Ziganshin AU, Chichirov AA. New Specific Marker of Cytochrome P450 1A2 Activity. Bull Exp Biol Med 2011;150:762-4. [DOI: 10.1007/s10517-011-1243-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Murray M, Zhang WV, Edwards RJ. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors. Basic Clin Pharmacol Toxicol 2018;122:388-95. [PMID: 29155491 DOI: 10.1111/bcpt.12933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
76 Lu AYH, Wang RW, Lin JH. Cytochrome P450 In Vitro Reaction Phenotyping: A Re-evaluation of Approaches Used for P450 Isoform Identification. Drug Metab Dispos 2003;31:345-50. [DOI: 10.1124/dmd.31.4.345] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
77 Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82:667-715. [PMID: 18618097 DOI: 10.1007/s00204-008-0332-8] [Cited by in Crossref: 356] [Cited by in F6Publishing: 317] [Article Influence: 27.4] [Reference Citation Analysis]
78 Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013;17:165-84. [PMID: 23588782 DOI: 10.1007/s40291-013-0028-5] [Cited by in Crossref: 193] [Cited by in F6Publishing: 148] [Article Influence: 24.1] [Reference Citation Analysis]
79 Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015;122:5-28. [DOI: 10.1007/s00702-014-1300-5] [Cited by in Crossref: 89] [Cited by in F6Publishing: 79] [Article Influence: 12.7] [Reference Citation Analysis]
80 Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-abreu P, Callegari-jacques SM, Gesteira A, Barros F, Carracedo Á, Hutz MH. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European–Brazilian schizophrenics. Pharmacogenetics and Genomics 2008;18:599-609. [DOI: 10.1097/fpc.0b013e328301a763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
81 Šimić I, Potočnjak I, Kraljičković I, Stanić Benić M, Čegec I, Juričić Nahal D, Ganoci L, Božina N. CYP2D6 *6/*6 genotype and drug interactions as cause of haloperidol-induced extrapyramidal symptoms. Pharmacogenomics 2016;17:1385-9. [PMID: 27469576 DOI: 10.2217/pgs-2016-0069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kharasch ED, Vangveravong S, Buck N, London A, Kim T, Blood J, Mach RH. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil. Clin Pharmacol Ther 2011;89:562-70. [PMID: 21346758 DOI: 10.1038/clpt.2010.313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
83 Seripa D, Lozupone M, Stella E, Paroni G, Bisceglia P, La Montagna M, D’onofrio G, Gravina C, Urbano M, Priore MG, Lamanna A, Daniele A, Bellomo A, Logroscino G, Greco A, Panza F. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? Expert Opinion on Drug Safety 2017;16:1373-85. [DOI: 10.1080/14740338.2017.1389891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
84 Gunes A, Scordo MG, Jaanson P, Dahl M. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology 2007;190:479-84. [DOI: 10.1007/s00213-006-0622-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
85 Szoeke CE, Newton M, Wood JM, Goldstein D, Berkovic SF, Obrien TJ, Sheffield LJ. Update on pharmacogenetics in epilepsy: a brief review. The Lancet Neurology 2006;5:189-96. [DOI: 10.1016/s1474-4422(06)70352-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 10] [Article Influence: 3.1] [Reference Citation Analysis]
86 von Grafenstein S, Fuchs JE, Huber MM, Bassi A, Lacetera A, Ruzsanyi V, Troppmair J, Amann A, Liedl KR. Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. J Breath Res 2014;8:046001. [PMID: 25233885 DOI: 10.1088/1752-7155/8/4/046001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Ruaño G, Villagra D, Rahim US, Windemuth A, Kocherla M, Bower B, Szarek BL, Goethe JW. Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Per Med 2008;5:579-87. [PMID: 29788619 DOI: 10.2217/17410541.5.6.579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
88 Callaway JC. Fast and Slow Metabolizers of Hoasca. Journal of Psychoactive Drugs 2005;37:157-61. [DOI: 10.1080/02791072.2005.10399797] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
89 Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37. [PMID: 14618296 DOI: 10.1007/s00210-003-0832-2] [Cited by in Crossref: 560] [Cited by in F6Publishing: 494] [Article Influence: 31.1] [Reference Citation Analysis]
90 Oscarson M. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine. Clinical Chemistry and Laboratory Medicine 2003;41. [DOI: 10.1515/cclm.2003.087] [Cited by in Crossref: 51] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
91 Waade RB, Solhaug V, Høiseth G. Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol. Br J Clin Pharmacol 2021;87:2228-35. [PMID: 33118660 DOI: 10.1111/bcp.14626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
92 Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, Pirmohamed M, Walley T. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011;11:1-14. [PMID: 20877299 DOI: 10.1038/tpj.2010.73] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
93 Kim YM, Yoo SH, Kang RY, Kim MJ, Bae YY, Lee YK, Jeon SJ, Chon KJ, Shin SM, Kim SG, Park KH, Son IJ. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. American Journal of Health-System Pharmacy 2007;64:166-75. [DOI: 10.2146/ajhp050490] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
94 Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosc 2008;258:12-20. [DOI: 10.1007/s00406-007-1004-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
95 Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008;42:884-93. [PMID: 18086475 DOI: 10.1016/j.jpsychires.2007.10.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
96 Hirano R, Yokokawa A, Furuta T, Shibasaki H. Sensitive and simultaneous quantitation of 6β-hydroxycortisol and cortisol in human plasma by LC-MS/MS coupled with stable isotope dilution method. J Mass Spectrom 2018;53:665-74. [DOI: 10.1002/jms.4200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
97 Hood S, Orr K, Bennett L, Davies S. Severe Laryngeal Dystonia in a Patient Receiving Zuclopenthixol “Acuphase” and Fluoxetine. Australas Psychiatry 2010;18:174-6. [DOI: 10.3109/10398560903473686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]